3SBio Inc. has announced the signing of an exclusive licensing agreement with Pfizer Inc. for the development of a PD-1/VEGF bispecific antibody known as SSGJ-707. This agreement is a strategic move aimed at bringing the innovative treatment to patients worldwide. Additionally, 3SBio revealed that there is a possibility of Pfizer subscribing to a number of new shares of the company, although no binding agreement has been reached on this potential subscription. The company advises shareholders and potential investors to exercise caution when dealing with its shares. The agreement also includes an option for Pfizer to commercialize the licensed product in mainland China, pending regulatory approvals. Morgan Stanley Asia Limited and Han Kun Law Offices are advising 3SBio on this transaction.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。